Biotek-snakken — Oktober 2024
-
Altid svært at sammenligne aftaler, når man ikke kender ret mange detaljer - 2,1 milliard dollars i milestonebetalinger nok det mest prangende, men sikkert på bekostning andre steder. Men men men degraders fylder stille og roligt mere og mere i landskabet.
-
Bioporto indgår aftale med Beckman Coulter om distribution https://proinvestor.com/investornyt/1233817/bioporto-indgar-aftale-med-beckman-coulter-om-distribution
-
AbbVie adds anti-amyloid asset to its CNS repertoire in $1.4B-buyout of Aliada https://firstwordpharma.com/story/5907150
-
Biogen And Neomorph Collaborate To Develop Molecular Glue Degraders For Alzheimer's And More https://proinvestor.com/investornyt/1234743/biogen-and-neomorph-collaborate-to-develop-molecular-glue-degraders-for-alzheimers-and-more
-
Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very Low Birth Weight Infants
NIH VideoCast - Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very Low Birth Weight Infants
The Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (collectively, we) are announcing a public workshop entitled “Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very Low Birth Weight Infants.” The purpose of the public workshop is to exchange information with the medical and scientific community about the regulatory and scientific issues associated with use of live biotherapeutic products to prevent necrotizing enterocolitis (NEC) in very low birth weight (VLBW) infants.
For more information go to https://web.cvent.com/event/7d104839-6b90-4934-aff3-7c273ea4256a/summaryNIH VideoCast (videocast.nih.gov)
IBT på FDA-workshoppen i USA ..
-
Lundbeck fremlægger positive fase 3-resultater med migrænemiddel https://proinvestor.com/investornyt/1235691/lundbeck-fremlaegger-positive-fase-3-resultater-med-migraenemiddel
til voksen brug ved Massachusetts General Hospital
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind